The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer – a multicentre observational study

Abstract

To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and MethodsThis was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries.

Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis

“…Therefore, cystoscopy remains as the gold standard in the investigation of visible hematuria. One could foresee a point of care test used by general practitioners and other nonurological specialists to select patients for fast-track referral to the urologist [57].…”

Haematuria: what is the real cancer risk? Results from the IDENTIFY study

“…This study would not be possible without the hard work of the many collaborators who contributed data, and the BURST core committee group that helped to analyse and disseminate the results. All authors are listed in the main IDENTIFY study paper 1 . We would also like to thank our funders, Action Bladder Cancer UK, The Urology Foundation and Rosetrees Trust.…”

“…The IDENTIFY study is the largest prospective international cohort study conducted among patients referred with haematuria to secondary care. It analysed data for over 11 000 patients from 26 countries in 110 hospitals 1 . It excluded patients with a previous or ongoing history of urological malignancy.…”

Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers

“…Hence, ongoing randomized trials should determine the benefits of using biomarkers in a large patient group (NCT03988309) [ 10 ]. A point-of-care urine test that general physicians can use to select patients for fast-track referral to the urologist should thus urgently be developed [ 11 ].…”